17,261 trials
Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate — 37.5; 5.9; 0; 16.7 percentage of patients
Osteopetrosis
Primary: Number of Participants With Treatment Related Adverse Events CTCAE v4.0 Grade 3 or Higher — 0 Participants
Amyotrophic Lateral Sclerosis
Primary: Number of Participants Who Had Any Serious Adverse Events or Any Adverse Events With Severity Higher Than "Moderate". — 0; 0 Participants
Graft Versus Host Disease · Hematopoietic/Lymphoid Cancer
Primary: 12 Month Disease Free Survival Probability — 51.8 percentage of participants
Fragile X Syndrome
Primary: Change in Weighted Child Intentional Communication Score — 0.14; 0.04 log10(scores on a scale) — p=0.1587
Schizophrenia, Schizoaffective Disorder
Primary: Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — 99.38; 98.54; 100.53; 100.03 Units on a scale — p=0.849
Allografts · Rejection; Transplant, Kidney · Transplant Rejection
Primary: Percentage of Participants With Treated Biopsy-proven Acute Rejection (tBPAR) of Grade 1A or Higher, Graft Loss or Death at Week 24 — 25.0 percentage of participants
Influenza, Human
Primary: Percentage of Seroprotected Participants for Anti-hemagglutination Inhibition (HI) Antibodies Against Vaccine-homologous H7N9 — 27.1; 27.7; 23.5; 26.5 Percentage of…
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: MTD, Defined as the Highest Dose in Which =< 1/6 Patients Experience a Dose-limiting Toxicity, Graded According to the National Cancer Institute Common Terminology…
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With CR at EOI Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography…
Leukemia · Myelodysplastic Syndromes
Primary: Overall Survival at 5 Years Post-Transplant. — 40 percentage of survival probability
Metastatic Triple Negative Breast Cancer
Primary: Overall Response Rate (ORR) in Patients Treated With CNP — 2; 11; 6; 8 Participants
Non-infectious Anterior Uveitis
Primary: Assessment of Both Systemic and Ocular Adverse Events — 2; 5 Participants
Chronic Low-back Pain
Primary: Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) at Week 4 — -1.28; -0.90 score on a scale
Sarcoidosis
Primary: Number of Participants Without Sarcoidosis Flare (Flare-Free Survival) — 2; 7 Participants